| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 18 | 2024 | 635 | 3.940 |
Why?
|
| Influenza, Human | 17 | 2024 | 925 | 3.240 |
Why?
|
| Immunogenicity, Vaccine | 13 | 2024 | 86 | 3.140 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 5 | 2024 | 25 | 2.680 |
Why?
|
| Vaccines | 6 | 2023 | 389 | 1.930 |
Why?
|
| Antibodies, Viral | 26 | 2024 | 1320 | 1.550 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 2 | 2020 | 14 | 1.440 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 5 | 2021 | 68 | 1.320 |
Why?
|
| Immunization, Secondary | 8 | 2022 | 110 | 1.320 |
Why?
|
| HIV Infections | 9 | 2019 | 2134 | 1.240 |
Why?
|
| Antibodies, Neutralizing | 17 | 2023 | 541 | 1.090 |
Why?
|
| Hemagglutination Inhibition Tests | 12 | 2024 | 159 | 1.060 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2013 | 426 | 1.050 |
Why?
|
| Adjuvants, Immunologic | 10 | 2024 | 657 | 1.040 |
Why?
|
| Vaccines, Inactivated | 9 | 2023 | 175 | 0.960 |
Why?
|
| Tuberculosis | 5 | 2014 | 548 | 0.900 |
Why?
|
| Bacteremia | 2 | 2019 | 689 | 0.760 |
Why?
|
| Zika Virus | 4 | 2023 | 144 | 0.740 |
Why?
|
| Influenza in Birds | 1 | 2020 | 26 | 0.740 |
Why?
|
| Polysorbates | 5 | 2024 | 25 | 0.730 |
Why?
|
| Squalene | 5 | 2024 | 21 | 0.730 |
Why?
|
| Microcephaly | 1 | 2023 | 325 | 0.730 |
Why?
|
| Zika Virus Infection | 4 | 2023 | 166 | 0.720 |
Why?
|
| Clostridium septicum | 1 | 2019 | 2 | 0.710 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2019 | 2 | 0.710 |
Why?
|
| Antitubercular Agents | 4 | 2013 | 318 | 0.650 |
Why?
|
| Encephalitis | 1 | 2019 | 143 | 0.650 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 419 | 0.630 |
Why?
|
| Vaccination | 11 | 2023 | 1123 | 0.630 |
Why?
|
| Hemagglutinins | 2 | 2021 | 39 | 0.630 |
Why?
|
| Amebiasis | 1 | 2017 | 15 | 0.620 |
Why?
|
| Acanthamoeba | 1 | 2017 | 17 | 0.620 |
Why?
|
| Population Surveillance | 5 | 2013 | 627 | 0.620 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 40 | 0.600 |
Why?
|
| Anthrax Vaccines | 5 | 2016 | 26 | 0.560 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 418 | 0.540 |
Why?
|
| Clostridium Infections | 1 | 2019 | 252 | 0.530 |
Why?
|
| Francisella tularensis | 2 | 2017 | 19 | 0.510 |
Why?
|
| Humans | 87 | 2024 | 261506 | 0.500 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 333 | 0.500 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 103 | 0.490 |
Why?
|
| Immunization Schedule | 5 | 2017 | 117 | 0.470 |
Why?
|
| Seizures | 1 | 2019 | 989 | 0.470 |
Why?
|
| Adult | 46 | 2023 | 77950 | 0.460 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 242 | 0.450 |
Why?
|
| Disease Outbreaks | 2 | 2008 | 415 | 0.440 |
Why?
|
| Guatemala | 5 | 2023 | 67 | 0.430 |
Why?
|
| Urban Population | 1 | 2013 | 269 | 0.420 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.420 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2005 | 247 | 0.420 |
Why?
|
| Antibodies, Bacterial | 7 | 2017 | 380 | 0.410 |
Why?
|
| Aza Compounds | 1 | 2011 | 25 | 0.400 |
Why?
|
| Double-Blind Method | 15 | 2023 | 2588 | 0.400 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 1390 | 0.390 |
Why?
|
| Malaria Vaccines | 1 | 2010 | 20 | 0.380 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 66 | 0.370 |
Why?
|
| Malaria, Falciparum | 1 | 2010 | 46 | 0.370 |
Why?
|
| Young Adult | 20 | 2023 | 21445 | 0.370 |
Why?
|
| Antigens, Viral | 1 | 2012 | 471 | 0.360 |
Why?
|
| Protozoan Proteins | 1 | 2010 | 114 | 0.350 |
Why?
|
| Orthomyxoviridae | 2 | 2011 | 94 | 0.350 |
Why?
|
| Male | 43 | 2023 | 123000 | 0.340 |
Why?
|
| Anthrax | 3 | 2014 | 36 | 0.330 |
Why?
|
| Child Development | 2 | 2021 | 255 | 0.320 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2022 | 222 | 0.320 |
Why?
|
| Immunoglobulin G | 9 | 2023 | 1021 | 0.320 |
Why?
|
| Quinolines | 1 | 2011 | 383 | 0.310 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.310 |
Why?
|
| Adolescent | 25 | 2023 | 31252 | 0.310 |
Why?
|
| Middle Aged | 32 | 2023 | 86204 | 0.310 |
Why?
|
| RNA, Viral | 2 | 2021 | 671 | 0.300 |
Why?
|
| Vaccines, Synthetic | 6 | 2022 | 355 | 0.280 |
Why?
|
| Smallpox Vaccine | 2 | 2017 | 43 | 0.280 |
Why?
|
| Brain | 1 | 2019 | 4113 | 0.280 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 61 | 0.270 |
Why?
|
| Female | 42 | 2023 | 141928 | 0.270 |
Why?
|
| Organophosphonates | 1 | 2006 | 64 | 0.270 |
Why?
|
| RNA, Messenger | 4 | 2023 | 6150 | 0.260 |
Why?
|
| Viral Vaccines | 2 | 2022 | 304 | 0.260 |
Why?
|
| China | 2 | 2024 | 606 | 0.260 |
Why?
|
| Placebos | 5 | 2016 | 437 | 0.250 |
Why?
|
| Patient Acuity | 2 | 2021 | 72 | 0.250 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 8 | 0.240 |
Why?
|
| Azetidines | 2 | 2022 | 87 | 0.240 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2005 | 123 | 0.240 |
Why?
|
| Creatinine | 1 | 2006 | 531 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 362 | 0.240 |
Why?
|
| Single-Blind Method | 2 | 2021 | 409 | 0.230 |
Why?
|
| Injections, Intramuscular | 8 | 2022 | 255 | 0.230 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2017 | 73 | 0.230 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 30 | 0.230 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 1450 | 0.230 |
Why?
|
| Water Microbiology | 1 | 2002 | 22 | 0.220 |
Why?
|
| Texas | 8 | 2013 | 6311 | 0.220 |
Why?
|
| Adenine | 1 | 2006 | 631 | 0.220 |
Why?
|
| Aedes | 1 | 2023 | 92 | 0.220 |
Why?
|
| Water Supply | 1 | 2002 | 24 | 0.220 |
Why?
|
| Purines | 2 | 2022 | 273 | 0.220 |
Why?
|
| Mycobacterium Infections | 1 | 2002 | 49 | 0.220 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 447 | 0.220 |
Why?
|
| Azithromycin | 1 | 2022 | 78 | 0.210 |
Why?
|
| Mycobacterium | 1 | 2002 | 56 | 0.210 |
Why?
|
| Cough | 1 | 2023 | 116 | 0.210 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.210 |
Why?
|
| Infant | 7 | 2023 | 13310 | 0.210 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 22 | 0.210 |
Why?
|
| Injections, Subcutaneous | 5 | 2017 | 334 | 0.200 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 130 | 0.200 |
Why?
|
| Growth Disorders | 1 | 2023 | 218 | 0.200 |
Why?
|
| Vomiting | 1 | 2023 | 354 | 0.200 |
Why?
|
| Vaccines, Attenuated | 3 | 2017 | 210 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 2594 | 0.190 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 76 | 0.190 |
Why?
|
| Pandemics | 4 | 2023 | 1559 | 0.190 |
Why?
|
| Emigration and Immigration | 1 | 2000 | 86 | 0.190 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 7789 | 0.190 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 82 | 0.190 |
Why?
|
| Incidence | 4 | 2021 | 5673 | 0.180 |
Why?
|
| Alanine | 1 | 2020 | 240 | 0.180 |
Why?
|
| Dengue Virus | 1 | 2021 | 123 | 0.180 |
Why?
|
| Dengue | 1 | 2021 | 109 | 0.180 |
Why?
|
| Mycobacterium avium Complex | 2 | 2021 | 29 | 0.180 |
Why?
|
| DNA, Bacterial | 3 | 2011 | 558 | 0.180 |
Why?
|
| Birds | 1 | 2020 | 92 | 0.180 |
Why?
|
| Lipid A | 1 | 2019 | 30 | 0.180 |
Why?
|
| Occupational Health | 1 | 2020 | 95 | 0.180 |
Why?
|
| Language Tests | 1 | 2019 | 27 | 0.180 |
Why?
|
| Diarrhea | 1 | 2023 | 686 | 0.170 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 105 | 0.170 |
Why?
|
| Motor Skills | 1 | 2020 | 107 | 0.170 |
Why?
|
| Schistosomiasis | 1 | 2019 | 63 | 0.170 |
Why?
|
| Glucosides | 1 | 2019 | 64 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 1489 | 0.170 |
Why?
|
| Clinical Trials as Topic | 5 | 2022 | 3719 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 332 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 2022 | 437 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2006 | 739 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 419 | 0.160 |
Why?
|
| Language Development Disorders | 1 | 2019 | 167 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2013 | 6100 | 0.160 |
Why?
|
| Body Fluids | 1 | 2019 | 125 | 0.160 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.160 |
Why?
|
| Tularemia | 1 | 2017 | 12 | 0.150 |
Why?
|
| Cross Infection | 1 | 2002 | 544 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 245 | 0.150 |
Why?
|
| Aged | 15 | 2023 | 70117 | 0.150 |
Why?
|
| Influenza B virus | 2 | 2023 | 127 | 0.150 |
Why?
|
| Vaccinia virus | 1 | 2017 | 79 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2022 | 32848 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 161 | 0.140 |
Why?
|
| Learning | 1 | 2020 | 403 | 0.140 |
Why?
|
| Cytokines | 3 | 2020 | 2809 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 241 | 0.130 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 330 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2017 | 327 | 0.130 |
Why?
|
| Pyrazoles | 2 | 2022 | 1471 | 0.130 |
Why?
|
| Coccidioidomycosis | 1 | 2015 | 32 | 0.130 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 31 | 0.130 |
Why?
|
| Caregivers | 1 | 2021 | 677 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 717 | 0.130 |
Why?
|
| Cholecystitis | 1 | 2015 | 52 | 0.130 |
Why?
|
| Sulfonamides | 2 | 2022 | 1823 | 0.130 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 12 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| United States | 7 | 2023 | 15433 | 0.130 |
Why?
|
| Health Personnel | 1 | 2020 | 625 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 3639 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2015 | 163 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2023 | 14889 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1230 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 317 | 0.110 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 170 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 709 | 0.110 |
Why?
|
| Molecular Epidemiology | 2 | 2005 | 246 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 29902 | 0.110 |
Why?
|
| Bacillus anthracis | 2 | 2009 | 44 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2022 | 9244 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Erythema Infectiosum | 1 | 2011 | 11 | 0.100 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 36 | 0.100 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 39 | 0.100 |
Why?
|
| Coinfection | 1 | 2013 | 189 | 0.100 |
Why?
|
| Child, Preschool | 6 | 2022 | 16273 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2011 | 41 | 0.100 |
Why?
|
| Psychometrics | 3 | 2021 | 937 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 297 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2011 | 55 | 0.100 |
Why?
|
| Mortality | 1 | 2013 | 343 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 5539 | 0.100 |
Why?
|
| Aluminum Compounds | 1 | 2010 | 17 | 0.100 |
Why?
|
| Prevalence | 2 | 2011 | 3260 | 0.100 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 126 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 589 | 0.090 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 87 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2022 | 12873 | 0.090 |
Why?
|
| Human Experimentation | 1 | 2010 | 51 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4367 | 0.090 |
Why?
|
| Plasmodium falciparum | 1 | 2010 | 65 | 0.090 |
Why?
|
| Phosphates | 1 | 2010 | 187 | 0.090 |
Why?
|
| Risk Factors | 4 | 2013 | 17523 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2011 | 994 | 0.090 |
Why?
|
| Animals | 7 | 2023 | 59536 | 0.090 |
Why?
|
| Influenza A virus | 1 | 2010 | 270 | 0.090 |
Why?
|
| Exanthema | 1 | 2011 | 211 | 0.080 |
Why?
|
| Injections, Intradermal | 3 | 2015 | 58 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 105 | 0.080 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 237 | 0.080 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 347 | 0.080 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 187 | 0.080 |
Why?
|
| HIV-1 | 1 | 2012 | 653 | 0.070 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2006 | 17 | 0.070 |
Why?
|
| Europe | 1 | 2008 | 649 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 543 | 0.070 |
Why?
|
| Tenofovir | 1 | 2006 | 23 | 0.070 |
Why?
|
| Logistic Models | 2 | 2005 | 3441 | 0.070 |
Why?
|
| Neutralization Tests | 2 | 2017 | 299 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6009 | 0.070 |
Why?
|
| Research | 1 | 2008 | 415 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 1029 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 1178 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1144 | 0.060 |
Why?
|
| Child | 5 | 2022 | 29154 | 0.060 |
Why?
|
| Pregnancy | 3 | 2023 | 7573 | 0.060 |
Why?
|
| Cities | 1 | 2004 | 49 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 4971 | 0.060 |
Why?
|
| Urban Health | 1 | 2004 | 75 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 3472 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 6089 | 0.060 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 46 | 0.060 |
Why?
|
| Carrier State | 1 | 2004 | 90 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 2483 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 218 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.060 |
Why?
|
| Aluminum Hydroxide | 1 | 2023 | 40 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7702 | 0.060 |
Why?
|
| Brazil | 1 | 2023 | 165 | 0.060 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 91 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2023 | 219 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 129 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 866 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 435 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 1099 | 0.050 |
Why?
|
| Bacterial Toxins | 2 | 2016 | 228 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 340 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 44 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 538 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2002 | 199 | 0.050 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 354 | 0.050 |
Why?
|
| Ethambutol | 1 | 2000 | 10 | 0.050 |
Why?
|
| Translations | 1 | 2020 | 39 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 119 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2000 | 144 | 0.040 |
Why?
|
| Child Language | 1 | 2019 | 15 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 63 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 64 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1225 | 0.040 |
Why?
|
| Rural Health | 1 | 2019 | 51 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 460 | 0.040 |
Why?
|
| Translating | 1 | 2019 | 45 | 0.040 |
Why?
|
| Age Distribution | 1 | 2000 | 698 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 42 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 178 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 90 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 4298 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2000 | 1053 | 0.040 |
Why?
|
| Serogroup | 1 | 2017 | 50 | 0.040 |
Why?
|
| Agglutination Tests | 1 | 2017 | 7 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 281 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 231 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 754 | 0.040 |
Why?
|
| Seroconversion | 1 | 2017 | 19 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 410 | 0.040 |
Why?
|
| Time Factors | 1 | 2012 | 12926 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 3203 | 0.040 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 48 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 23 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 577 | 0.040 |
Why?
|
| Baculoviridae | 1 | 2017 | 86 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 1450 | 0.040 |
Why?
|
| Emulsions | 1 | 2017 | 82 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2017 | 182 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2992 | 0.040 |
Why?
|
| Vagina | 1 | 2019 | 317 | 0.040 |
Why?
|
| Milk, Human | 1 | 2019 | 277 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 4314 | 0.030 |
Why?
|
| Hemagglutination, Viral | 1 | 2015 | 10 | 0.030 |
Why?
|
| Recurrence | 1 | 2004 | 4758 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 84 | 0.030 |
Why?
|
| alpha-Tocopherol | 1 | 2015 | 78 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2315 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 397 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1274 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 1544 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2015 | 621 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2015 | 147 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2013 | 383 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 324 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 2083 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 4938 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2004 | 6869 | 0.020 |
Why?
|
| Pharynx | 1 | 2011 | 153 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2011 | 185 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 598 | 0.020 |
Why?
|
| New York | 1 | 2009 | 104 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2009 | 137 | 0.020 |
Why?
|
| Nose | 1 | 2011 | 192 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 5687 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 3869 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8223 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 957 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 503 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 465 | 0.020 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 10 | 0.010 |
Why?
|
| Mice | 1 | 2023 | 34495 | 0.010 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2000 | 3 | 0.010 |
Why?
|
| Operon | 1 | 2000 | 53 | 0.010 |
Why?
|
| Pentosyltransferases | 1 | 2000 | 25 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 37905 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 677 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 2283 | 0.010 |
Why?
|